Status:
UNKNOWN
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
Lead Sponsor:
Sunshine Specialty Health Care
Conditions:
HIV Infections
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.
Eligibility Criteria
Inclusion
- HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more.
- BMI increase of 10% or more since initiation of HIV treatment over a year period.
- BMI equal to or greater than 30.
- 18-85 years of age.
Exclusion
- Cancer
- Pregnancy or breastfeeding
- Intolerance to cruciferous vegetables
- Intolerance to sulforaphane
- Gluten Intolerance
- Creatinine \> 1.3 mg/dL
- GFR \< 60
- AST or ALT \> 1.5 times upper limit of normal.
- White cell count \< 2000 cells per ml.
- Hemoglobin \< 10.5 g/dL.
- Platelet count \< 140,000 per ml.
Key Trial Info
Start Date :
February 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 21 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05224492
Start Date
February 21 2022
End Date
September 21 2022
Last Update
February 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.